Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. The company is headquartered in Berwyn, Pennsylvania and currently employs 2 full-time employees. The company went IPO on 2021-02-17. The firm is focused on developing novel and proprietary drug delivery systems across various pain indications. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
Follow-Up Questions
What is the price performance of VRPX stock?
The current price of VRPX is $0.0151, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Virpax Pharmaceuticals Inc?
Virpax Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Virpax Pharmaceuticals Inc market cap?
Virpax Pharmaceuticals Inc's current market cap is $19328
Is Virpax Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Virpax Pharmaceuticals Inc, including 0 strong buy, 0 buy, 3 hold, 1 sell, and 0 strong sell
